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Abstract: Iron is at the forefront of a number of pivotal biological processes due to its ability to
readily accept and donate electrons. However, this property may also catalyze the generation of
free radicals with ensuing cellular and tissue toxicity. Accordingly, throughout evolution numerous
pathways and proteins have evolved to minimize the potential hazardous effects of iron cations and
yet allow for readily available iron cations in a wide variety of fundamental metabolic processes.
One of the extensively studied proteins in the context of systemic and cellular iron metabolisms is
ferritin. While clinicians utilize serum ferritin to monitor body iron stores and inflammation, it is
important to note that the vast majority of ferritin is located intracellularly. Intracellular ferritin is
made of two different subunits (heavy and light chain) and plays an imperative role as a safe iron
depot. In the past couple of decades our understanding of ferritin biology has remarkably improved.
Additionally, a significant body of evidence has emerged describing the significance of the kidney in
iron trafficking and homeostasis. Here, we briefly discuss some of the most important findings that
relate to the role of iron and ferritin heavy chain in the context of kidney-related diseases and, in
particular, vascular calcification, which is a frequent complication of chronic kidney disease.
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1. The Superfamily of Ferritins
The ability of iron cations (the second most abundant element on earth) to change its valence
serves as a unique and central capacity to contribute in multiple biological pathways, yet underscores
its potential hazardous effects mainly by participating in Fenton’s reaction [1,2].
O2− + Fe3+←→O2 + Fe2+
Fe2+ + H2O2→Fe3+ + HO + OH− (Fenton’s reaction)
O2− + H2O2←→O2 + HO + OH− (Haber–Weiss reaction)
The discovery of ferritin, a protein isolated from horse spleen, was a major step in our understanding of
iron metabolism [3]. This discovery was followed by numerous studies that examined this multifaceted
protein in various aspects of physiological and pathological conditions [4]. The highly conserved
structure of ferritin and its universal expression among species further highlights the importance of this
protein at the crossroads of multiple biological pathways that are mainly dictated by iron trafficking
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and homeostasis [4–6]. Ferritin is a globular protein made up of 24 subunits with a spherical hollow
shell that allows for the safe storage of up to 4500 atoms of Fe3+. These subunits are composed of heavy
(FtH) and light (FtL) chains and their proportional contribution to the hollow spherical shell depends
on the tissue and developmental stage of the organism [5,7]. For instance, while brain and heart ferritin
is primarily composed of FtH chains, the liver and spleen mainly possess FtL [7]. One intriguing
aspect of ferritin biology relates to serum ferritin that is predominantly composed of FtL chain, as
evidenced by immunological cross reactivity with anti-ferritin L antibodies [8–10]. Serum ferritin
is also relatively iron poor and its source was not completely understood until it was revealed by
Cohen and colleagues that macrophages are the primary source of serum ferritin [11]. It must be noted
that several investigators have reported that other cells, particularly hepatocytes, are also capable of
secreting ferritin [12–14]. The study by Cohen et al. elegantly confirmed the light chain predominance
of serum ferritin and its relatively low iron cations content, and provided evidence to support its
secretion through the non-classical lysosomal secretory pathway [11]. More recently, another study
reported that secretion of ferritin is mediated through two distinct non-classical pathways [15]. This
study also examined the release of iron-rich ferritin and demonstrated that such secretion occurs via the
multivesicular body-exosome pathway [15]. The release of iron-rich ferritin is particularly interesting
as it may serve as an iron cargo predominantly in a paracrine fashion. The receptors, precise mode of
uptake, and relevance of ferritin uptake by cells among species continues to be debated in the literature
and future studies are needed to unequivocally describe the nature and significance of these processes.
Serum ferritin has long been used by clinicians to assess body iron stores in humans. However,
it is also recognized that levels of serum ferritin rise in response to a number of clinical conditions
particularly during inflammatory states and injury models, such as AKI [16–18]. Such elevation in
response to inflammatory stimuli and the relatively iron-poor status of serum ferritin resulted in
investigations to examine other potential roles in health and disease that were reviewed by Wang and
colleagues [19]. More recently, an interesting pilot study examined the feasibility of measuring urinary
ferritin (FtL) as a non-invasive diagnostic approach to assess neonates and young children for iron
deficiency or iron overload [20]. This study was based on previous reports that confirmed the presence
of urinary ferritin in healthy individuals [21,22] and, despite some limitations, found a correlation with
paired serum ferritin. In contrast to FtL, the FtH subunit has crucial ferroxidase activity that converts
Fe2+ to Fe3+, facilitating its safe storage in the form of mineral ferrihydrite within the inner wall of
the sphere [23,24]. Such functional properties have led to a significant amount of investigations into
this field, leading to the discovery of seminal findings into the role of this superfamily of proteins in
physiological processes and injury models [4,6,25,26].
The first description of a function for ferritin other than mere iron cation storage was reported
by Balla and colleagues [27]. This seminal manuscript described an anti-oxidant role for ferritin in
endothelial cells. In this study authors validated the cytotoxic properties of heme, but surprisingly found
that briefly pulsing cells with heme remarkably increased their resistance against oxidant-mediated
injury. While administration of apoferritin mimicked these beneficiary effects, a site-directed mutant
form of FtH with subsequent loss of ferroxidase activity failed to recapitulate such protection against
oxidative damage [27]. These findings generated significant interest in this field and were followed by
additional pivotal findings. For instance, while ferritin was traditionally regarded as a cytosolic protein,
others demonstrated its localization in other subcellular compartments, such as mitochondria [28,29]
and the nucleus [30–32]. This review is intended to briefly discuss some of the aspects of ferritin
in the context of kidney-related diseases and one of its major cardiovascular complications, namely
vascular calcification.
2. Role of Iron and Ferritin in Acute Kidney Injury
Acute kidney injury (AKI) is a common clinical syndrome characterized by a sudden decrement
in kidney function with ensuing derangements in multiple essential physiological parameters, such as
dysregulated volume and electrolyte homeostasis [33,34]. It is well documented that AKI increases
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morbidity and mortality, particularly among critically ill patients [33,35,36]. Moreover, AKI incidence is
on the rise and patients who survive AKI have an increased risk for the development of chronic kidney
disease (CKD) [37–39]. These detrimental clinical consequences have led to vigorous investigations to
better understand the individual and overlapping pathways that are involved in the pathogenesis of
AKI. Iron metabolism and trafficking has emerged as one such pathway. The kidney was not considered
a major organ involved in the regulation of iron homeostasis, mainly because of the lack of evidence of
its involvement in hereditary hemochromatosis and the assumption that transferrin bound iron cations
are not filtered by the glomerulus. However, along with other recent breakthroughs in the field of
iron metabolism, our understanding of the delicate and well-orchestrated iron regulatory machinery
in the kidney has evolved thanks to a number of pivotal observations. For example, the urinary
proteomic analysis of Fanconi syndrome, which is characterized by overall dysfunctional proximal
tubules and poor reabsorption capacity, demonstrates significantly elevated levels of transferrin in the
urine samples of subjects, confirming its filtration [40,41]. Transferrin can be reabsorbed in the tubules
via transferrin receptor-1 or cubilin-mediated endocytosis [42,43]. The kidneys also express high levels
of divalent metal transporter-1, which was first described by Gunshin et al. [44], and their importance
in renal iron handling under physiological and pathological conditions was subsequently confirmed by
other investigations [45–49]. Some other iron regulatory proteins that are expressed in kidneys include
neutrophil gelatinase-associated lipocalin [50], ferroportin [51,52], as well as hepcidin [53]. Additionally,
among other tissues, mouse kidney expresses the highest levels of iron regulatory protein-1 with
important functions in renal iron cations handling [54]. It must also be noted that the proximal tubules,
workhouse of nephrons, possess a significant amount of mitochondria that contain notable amounts of
heme, which encloses iron cations in its porphyrin ring. Based on the aforementioned evidence, it is
apparent that the kidneys, particularly proximal tubules, are heavily involved in iron trafficking under
both physiological and pathological conditions, and are accordingly more susceptible to injury [55]. In
fact, several lines of evidence suggest a role for iron cations-mediated kidney injury in both humans
and animal models of kidney disease [56–59]. The participation of iron cations in Fenton’s reaction
and their ability to aggravate oxidative stress led to the hypothesis that their removal would prove
beneficial in kidney injury. In support of this premise, multiple investigations demonstrated that the
removal of iron cations via deferoxamine (DFO), a potent iron cations chelator, was protective against
AKI. These studies utilized DFO in the setting of glycerol-induced rhabdomyolysis [60], hemoglobin-
and myoglobin-induced AKI [61], gentamicin nephrotoxicity [62], and ischemia-reperfusion (I/R) [63].
Notably, these salutary effects were recapitulated by the administration of apotransferrin in a model of
I/R-mediated AKI [64]. The evidence to suggest iron as a main culprit and mediator of AKI has also
been demonstrated in human studies. Work by Leaf and colleagues focused on the association between
catalytic iron cations, non-transferrin bound iron cations, and the course of AKI in patients undergoing
cardiac surgery with cardiopulmonary bypass [65]. They reported that primary outcomes, defined as
in-hospital death or need for renal replacement therapy, AKI, and other adverse events post-operatively,
were directly associated with higher plasma catalytic iron cation levels on post-operative day one [65].
In another study, the same group examined such association in 121 critically ill patients admitted to
medical or surgical intensive care units [66]. Similarly, higher plasma catalytic iron cation levels were
associated with a greater risk of death/need for renal replacement therapy, AKI, and hospital mortality.
Importantly, the authors stated that these associations are independent of age, estimated glomerular
filtration rate, and number of packed red blood cell transfusions [66]. Others also evaluated the role
of plasma catalytic iron cations in relation to contrast-induced nephropathy. Their results confirmed
higher levels of catalytic iron cations were associated with a higher risk of contrast nephropathy, as
well as higher rates of mortality [67]. Other studies have suggested a role for catalytic iron cations in
the context of glomerulopathies and proteinuria. For instance, in a rat model of nephrotic syndrome, a
significant increase in the levels of glomerular catalytic iron cations was observed [68]. Importantly,
chelation of iron cations with DFO was associated with complete protection against proteinuria [68].
Another clinical study validated these findings, where deferiprone, an oral iron cation chelator, was
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used in diabetic and non-diabetic glomerular disease [69]. While this study was rather small and
non-randomized, iron cation chelation demonstrated a marked reduction of proteinuria in both groups
of patients with and without diabetic glomerular nephropathy.
The above-mentioned evidence led to further investigations to examine how the proximal
tubular expression of ferritin may affect the course of AKI. The importance and non-redundant
function of FtH and its ferroxidase activity was reported by Ferreira and colleagues [70]. They
demonstrated that global deletion of FtH in mice leads to embryonic lethality between 3.5 and
9.5 days of development [70]. Therefore, to understand the role of proximal tubule FtH expression
during AKI, we generated transgenic mice with conditional deletion of FtH in proximal tubules.
This was achieved by crossing FtHlox/lox mice that were generated and characterized by Darshan
and colleagues [71] with phosphoenolpyruvate carboxykinase (PEPCK)-Cre mice [72]. Targeted
deletion of FtH in proximal tubules led to heightened rhabdomyolysis-induced AKI, as evidenced
by the higher rate of mortality, serum creatinine, and the higher expression of cleaved caspase-3, a
marker of apoptosis [18]. The protective nature of FtH expression in proximal tubules was further
supported by a histological analysis that revealed a greater number of tubular casts, necrotic tubules,
and more prominent loss of proximal tubule brush border in the absence of FtH expression. Notably,
rhabdomyolysis is primarily a heme-mediated injury model, given the significant amount of heme
present in myoglobin. Therefore, to investigate whether FtH may play a protective role in other
models of AKI that are not predominantly heme driven, cisplatin nephrotoxicity was used. These
results indicated that, irrespective of the model of injury, deletion of FtH led to worse renal function,
as evidenced by serum creatinine. Furthermore, the overall architecture of the kidneys was less
preserved in the absence of FtH [18]. These studies led to another interesting observation that FtH
deletion was accompanied by markedly higher levels of heme oxygenase-1 (HO-1) expression. HO-1
is a well-characterized anti-oxidant enzyme that has been shown to have protective effects against
a number insults and kidney injury models [73,74]. Aggravated AKI, despite such high levels of
HO-1, indicates that beneficial effects of HO-1 are co-dependent on FtH expression and this premise is
further supported in a model of rodent anti-thymocyte antigen-1-induced glomerulonephritis [75].
This study showed that inhibition of HO activity was accompanied with downregulation of FtH
expression and enhanced mesangial cell death. Additionally, while induction of HO-1 in cultured rat
mesangial cells augmented its resistance to oxidative stress, FtH knockdown by RNA interference
caused loss of such protective influences. Also of note, this study demonstrated adjacent expression of
HO-1 and FtH in inflammatory glomeruli of human lupus nephritis biopsies [75]. In another study,
Hatcher and colleagues examined FtH overexpression in a model of ischemia-reperfusion-induced
AKI [76]. Using a conditional tissue-specific doxycycline-inducible system, about 6.5-fold higher levels
of FtH expression was shown in mouse kidneys. Following injury, the authors demonstrated that
FtH overexpression was associated with lesser apoptosis and improved tubular viability [76]. It was
concluded that FtH overexpression protects the kidney via limiting oxidative stress induced by I/R.
Another line of evidence to support the role of FtH in protecting the kidney against injurious insults
comes from a more recent study by Scindia and colleagues [77]. In this study, the authors examined how
modulation of iron homeostatic pathways via hepcidin alters the course of I/R-induced AKI. Hepcidin,
a hormone produced primarily by hepatocytes [78], acts by directly binding to ferroportin, leading to
its internalization and subsequent degradation in lysosomes [79]. This eventually leads to decreased
iron cation absorption, as well as increased iron cation retention with subsequent upregulation of
intracellular ferritin. It was demonstrated that hepcidin, given 24–48 h before I/R, mitigated kidney
injury and reduced renal and systemic inflammation caused by I/R [77]. These effects were attributed
to increased FtH expression in the kidney and the spleen. These overall beneficial properties were also
corroborated in a model of hemoglobin-induced AKI, where hepcidin administration mitigated the
upregulation of urinary kidney injury markers (neutrophil gelatinase-associated lipocalin and kidney
injury molecule-1) and renal Interleukin-6 [80].
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To further elaborate on the role of FtH and how its expression in different cells may contribute to
the course of kidney damage, effects of FtH expression in myeloid cells were further investigated [81].
Using transgenic mice with conditional deletion of FtH in the proximal tubules or myeloid cells, it
was found that myeloid FtH deficiency did not affect activation or accumulation of macrophages in
the injured kidney compared with wild-type littermate controls. In contrast, a significant increase
in the number of pro-inflammatory macrophages accompanied FtH deletion in proximal tubules in
a model of unilateral ureteral obstruction (UUO). Moreover, while deletion of FtH in the myeloid
compartment resulted in lesser fibrosis in a UUO model of kidney injury, the lack of FtH expression
in proximal tubules exacerbated both inflammation and fibrosis [81]. These findings suggest a
central role for FtH expression in various compartments that underscores its importance in the
context of tubular-macrophage cross-talk during kidney injury. More recently, the effects of FtH
expression in myeloid cells during sepsis and its clinical sequelae, including sepsis-induced AKI, were
examined [82]. Results of this study demonstrated that the deletion of FtH in the myeloid compartment
was associated with marked protection in two models of sepsis, namely cecal ligation puncture and
lipopolysaccharide-induced endotoxemia. Deletion of FtH led to improved survival, reduced cytokine
levels, and more preserved renal function. Mechanistic studies revealed that the protective effects were
primarily mediated by the compensatory increase in circulating ferritin (FtL) in the absence of myeloid
FtH [82]. It must be noted that the main circulatory form of ferritin is FtL and macrophages have been
shown to be the primary source of serum ferritin [11]. Results also demonstrated that the protective
effects of FtL during sepsis are attributed to its inhibitory actions against the activation of the NF-κB
pathway. These findings not only provide a novel platform for future studies to better understand the
pathogenesis of sepsis but also shed light on the immunomodulatory roles of circulating FtL.
3. Ferritin: A Potent Inhibitor of Osteoblastic Activity
Cardiovascular-related diseases remain the foremost cause of death in patients with CKD and
those requiring renal replacement therapy [83–85]. About 10–15% of the U.S. population is estimated to
have CKD and more than 450,000 Americans require dialysis resulting in a major burden of morbidity,
mortality, and healthcare expenditure [86]. In this regard, vascular calcification (VC) is a common
complication of CKD and is recognized as a portentous contributing factor to cardiovascular death
in these patients [87–90]. The prevalence of VC is exceptionally high among patients with CKD
and can be observed even in very young dialysis patients [91,92]. Two distinct patterns of VC have
been described [93]. While intimal calcification occurs in atherosclerotic plaques, mineralization
of the medial compartment is a common pathological finding in aging patients and patients with
diabetes and advanced CKD [93,94]. The diffuse calcification that occurs in the medial layer of the
vasculature is an important marker for all-cause mortality in patients undergoing dialysis [87,88,95].
There are several detrimental hemodynamic consequences of VC, including loss of arterial elasticity,
increase in pulse wave velocity, development of left ventricular hypertrophy, and decrease in coronary
artery perfusion, ensuing in myocardial ischemia and failure [95,96]. Following the description of
VC as a tightly regulated cellular process where vascular smooth muscle cells (VSMC) transition
into “osteoblast-like” cells, major research efforts have identified various pathways and mechanisms
involved in the development and propagation of VC [97,98]. These proposed mechanisms include
elastin degradation, apoptosis of VSMC, release of exosomes loaded with microRNAs, and extracellular
vesicles that are rich in calcium and phosphate [99,100]. Nevertheless, multiple pivotal questions
remain unanswered and currently no therapies exist for the treatment or prevention of VC. To better
understand novel pathways that may be involved in the development and pathogenesis of VC, it was
important to examine how derangements in iron metabolism may be contributing to the development
of such detrimental pathological conditions. This principle was based on the fact that many patients
with advanced CKD are also predisposed to iron-restricted erythropoiesis. Several factors lead to the
development of anemia in patients with CKD and those requiring dialysis. These include decreased
erythropoietin production, frequent diagnostic testing, blood loss during hemodialysis, and cannula
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puncture sites following hemodialysis, as well as a “functional iron deficiency state” [101–104]. This
process, also known as anemia of chronic disease, is principally a result of the increased synthesis and
secretion of hepcidin, which is a common paradigm of chronic inflammatory states such as CKD [105].
It must be noted that other cytokines have been demonstrated to have additional effects and further
aggravate this state of functional iron deficiency [106]. Hepcidin leads to the internalization and
degradation of ferroportin (membrane iron transporter) and the overall outcome is the decreased iron
cation absorption from the small intestine along with the decreased egress of iron cations from the
reticuloendothelial system [105]. Accordingly, while macrophages are loaded with iron cations, other
cells within the body have a relatively lower iron cation content. It was therefore necessary to examine
whether the repletion of iron cations and the subsequent upregulation of ferritin in VSMC mitigates the
osteoblastic differentiation of these cells when exposed to high phosphate levels. Notably, increasing
levels of serum phosphorus manifest during advanced stages of CKD and such hyperphosphatemia is
a well-known risk factor for the development of VC [107–109]. Indeed, we found that the addition of
hemin was able to significantly arrest the calcification and osteoblastic transition of VSMC [110].
To identify the mediator of such a salutary effect, we examined products of the HO/ferritin system
that include biliverdin, bilirubin, carbon monoxide, and iron cations. It was demonstrated that iron
administration inhibited calcium deposition and led to about a five-fold increment in intracellular
ferritin levels. Subsequent studies using recombinant ferritin proteins confirmed the paramount role of
ferritin upregulation in this inhibitory process. Using exogenous recombinant FtH, FtL, and a mutant
form of FtH that lacks ferroxidase activity, we demonstrated the paramount role of FtH/ferroxidase
activity in the abrogation of VSMC mineralization and osteoblastic transformation [110]. Importantly,
the inhibitory role of FtH was not limited to the mere inhibition of hydroxyapatite deposition, but it
also prevented the expression of the core binding factor alpha-1 (cbfa-1), a key transcription factor in
osteogenesis [111].
Other studies have also suggested a potential inhibitory role for iron and iron-induced upregulation
of ferritin in the context of VC. For example, Rajendran et al. used various detection methods to
map the spatial distribution of the elements and quantify them simultaneously in atherosclerotic
rabbit arteries [112]. They demonstrated that within atherosclerotic plaques, iron cations (likely
sequestered within ferritin shell) and calcium exhibited a highly significant spatial inverse correlation.
Moreover, an adenine-induced model of CKD in rats was employed to investigate the role of PA-21, an
iron-based non-calcium phosphate binder in VC. They reported a higher degree of inhibition of VC
when compared to another frequently used phosphate binder, calcium carbonate [113]. Furthermore,
Seto et al. examined the role of iron loading on the progression of VC in an adenine diet-induced CKD
rat model [114]. It was demonstrated that iron loading resulted in the suppression of VC and attributed
these findings to the reduced expression of phosphate transporter (Pit-1) and cbfa-1. Others have also
reported the inhibition of high phosphate-induced VC using ferric citrate and attributed these results
to the suppression of apoptosis [115]. These results are interesting when taking into account a study
that was published in 1995 and reported the inhibition of calcium deposition in bioprostethic valves
when pre-treated with iron [116]. However, it is also noteworthy that some studies have failed to
recapitulate the overall inhibitory effects of iron during VC [117].
Based on these findings, we hypothesized that osteoporosis induced by iron overload states,
such as primary hemochromatosis [118,119], may be attributed to the increased expression of FtH in
osteoblasts secondary to excessive iron accumulation. Indeed, investigating the mechanism(s) leading
to decreased bone deposition in iron overload states, we were able to demonstrate the central role of
FtH in this process [120]. We showed that the administration of apoferritin or recombinant FtH (both
devoid of iron cations) markedly inhibited the mineralization and expression of osteoblastic specific
genes, such as osteocalcin, alkaline phosphatase, and cbfa-1 [120]. Overall these results confirmed
previous findings that increased iron cation levels mitigate calcification, but they also provided a novel
mechanism for this process and identified FtH upregulation as a main inhibitory factor in this regard.
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The potential hazardous effects of excessive iron cations are well recognized, and their optimal
dosage and utilization frequency in CKD patients have been a major point of debate among
nephrologists [121–123]. Accordingly, based on the aforementioned evidence, we sought to identify
other approaches to upregulate FtH expression in VSMC without using excessive iron and examine
how the pharmacological induction of ferritin may affect VC. To achieve this objective, we tested
the effects of 3H-1,2-Dithiole-3-thione (D3T), a well-known cancer chemopreventive agent [124] and
inducer of FtH expression [125], in a model of VSMC calcification. It was demonstrated that D3T
inhibited osteoblastic transition of VSMC in a dose-dependent manner [126]. However, the central role
of ferritin was further corroborated in experiments where the inhibitory effects of D3T on osteoblastic
transition were arrested during FtH knockdown by RNA interference [126]. The overall effect of
iron/D3T-induced FtH upregulation and inhibition of VSMC calcification is illustrated in Figure 1.
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to the deposition of extracellular Ca/Pi (hydroxyapatite crystals) and the activati n of osteoblastic
genes, i cluding OC (osteocalcin) and ALP (alkaline phosphatase). This process can be exacerbated
by the deletion of FtH (ferritin heavy chain) or mitigated via D3T (3H-1,2-Dithiole-3-thione) and Fe
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More recently, similar inhibitory effects in mitigating the calcification of valvular tissues were
demonstrated [127]. Valvular calcification and stenosis (particularly aortic valve) is a common finding
in patients undergoing dialysis and the elderly population. In this study we showed that the induction
of FtH was associated with the decreased osteoblastic activity of valvular interstitial cells. This
inhibitory effect was attributed to the reduced nuclear accumulation of cbfa-1, and as a reciprocal effect,
its enhancement of the nuclear localization of transcription factor Sox9 (SRY [sex-determining region
Y]-box 9) [127]. These findings provide additional support to previous observations that identified
reduced Sox9 function as a potential culprit of calcific valvular disease [128] and further corroborate
the “anti-osteoblastic activity” of FtH. It must be emphasized that while a significant body of evidence
is emerging to support the role of intracellular FtH expression as an inhibitory mechanism against
calcification, additional targeted studies in animal models are required to unequivocally demonstrate
and confirm these results.
It is also noteworthy that the implication and functional significance of iron and ferritin in the
context of atherosclerosis and coronary artery disease continues to generate contradicting results and
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is heavily debated in the literature. While we do not elaborate further on these studies in this review,
others have discussed these results in detail [129–134]
In conclusion, it is evident that ferritin and its role in both cellular and systemic iron homeostasis,
as well as its participation in a number of pathways that are central to various pathological conditions,
is increasingly recognized. Future studies and additional genetic manipulations (for instance, the
targeted deletion of FtL or the over-expression of FtH) would be germane to pave the way for potential
therapeutic targets utilizing this intriguing, ancient, and almost ubiquitous superfamily of proteins.
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